Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

Asa Dahle-Smith, Russell D Petty

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

Original languageEnglish
Pages (from-to)1103-1119
Number of pages17
JournalExpert Review of Anticancer Therapy
Volume15
Issue number9
Early online date2 Aug 2015
DOIs
Publication statusPublished - Sep 2015

Fingerprint

Stomach Neoplasms
Biomarkers
Climate
Immune System
Intercellular Signaling Peptides and Proteins
Delivery of Health Care
Drug Therapy
Survival
Therapeutics

Keywords

  • biomarkers
  • esophageal cancer
  • gastric cancer
  • targeted agents
  • translational medicine

Cite this

Biomarkers and novel agents in esophago-gastric cancer : are we making progress? / Dahle-Smith, Asa; Petty, Russell D.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 9, 09.2015, p. 1103-1119.

Research output: Contribution to journalArticle

Dahle-Smith, Asa ; Petty, Russell D. / Biomarkers and novel agents in esophago-gastric cancer : are we making progress?. In: Expert Review of Anticancer Therapy. 2015 ; Vol. 15, No. 9. pp. 1103-1119.
@article{0d4ef70f171346bdbc21de84e8286be0,
title = "Biomarkers and novel agents in esophago-gastric cancer: are we making progress?",
abstract = "Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.",
keywords = "biomarkers, esophageal cancer, gastric cancer, targeted agents, translational medicine",
author = "Asa Dahle-Smith and Petty, {Russell D}",
year = "2015",
month = "9",
doi = "10.1586/14737140.2015.1071669",
language = "English",
volume = "15",
pages = "1103--1119",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Biomarkers and novel agents in esophago-gastric cancer

T2 - are we making progress?

AU - Dahle-Smith, Asa

AU - Petty, Russell D

PY - 2015/9

Y1 - 2015/9

N2 - Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

AB - Esophago-gastric cancer (EGC) provides a formidable healthcare challenge. Conventional chemotherapy provides modest survival benefit in patients with advanced disease especially in the second-line setting. The recent paradigm shift in the oncology community towards targeting growth factor pathways and the immune system using novel targeted agents has now demonstrated clinical utility in EGC, but recent trial results have highlighted the complexity of disease pathogenesis and significant challenges remain. Here, we describe the current role of targeted therapies in EGC, and their corresponding biomarkers. We aim to provide a comprehensive review of the current climate of novel agents and their biomarkers in advanced EGC.

KW - biomarkers

KW - esophageal cancer

KW - gastric cancer

KW - targeted agents

KW - translational medicine

U2 - 10.1586/14737140.2015.1071669

DO - 10.1586/14737140.2015.1071669

M3 - Article

C2 - 26313419

VL - 15

SP - 1103

EP - 1119

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 9

ER -